PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...

The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory ...

Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...

Dr. Wen-Han Chang, corresponding author, added, “The work highlights why biomarkers cannot be interpreted in isolation. Tumor context—immune composition, metabolic state, and innate ...

Moleculin Biotech ( ($MBRX) ) just unveiled an announcement. On December 9, 2025, Moleculin Biotech announced an update on its pivotal Phase 2B/3 ...

Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) HoldersTAMPA, Fla., Dec. 15, 2025 /PRNewswire/ - ...

An immunomodulatory vaccine advancing to phase 3 trials highlights the evolving role of immune system recalibration in cancer treatment. From immunotherapy breakthroughs to early-stage scientific ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

Moleculin Biotech Inc. (NASDAQ:MBRX) moved higher in premarket trading on Tuesday, gaining 6.2% after the company announced ...

Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital ...

Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin” or the 'Company”), a late-stage pharmaceutical company with a broad ...